Litcius/Paper detail

Intermediate-risk Non–muscle-invasive Bladder Cancer: Recommendations for Definitions, Risk Stratification, Management Strategies, and Clinical Trial Design from the International Bladder Cancer Group

Roger Li, Patrick J. Hensley, Marko Babjuk, Laura Bukavina, Sarah P. Psutka, Seth P. Lerner, Michael A. O’Donnell, Yair Lotan, Kelly K. Bree, Joan Palou Redorta, David J. McConkey, Byron Lee, Paramananthan Mariappan, Laura S. Mertens, Mark S. Soloway, Robert S. Svatek, Wei Shen Tan, Stephen B. Williams, Shilpa Gupta, Roger Buckley, Ashish M. Kamat

2025European Urology Oncology6 citationsDOI

Topics & Concepts

MedicineClinical trialBladder cancerResearch designClinical study designInternal medicineOncologyMEDLINEIntensive care medicineClinical researchStandard of careClinical PracticeRandomized controlled trialPatient careRisk assessmentUrinary bladderDisease managementCancerBladder and Urothelial Cancer TreatmentsUrinary and Genital Oncology StudiesUrinary Bladder and Prostate Research
Intermediate-risk Non–muscle-invasive Bladder Cancer: Recommendations for Definitions, Risk Stratification, Management Strategies, and Clinical Trial Design from the International Bladder Cancer Group | Litcius